Literature DB >> 28638689

Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature.

Kyriakos Trigkidis1, Eleni Geladari1, Evangelos Kokkinakis1, Natalia Vallianou1.   

Abstract

There is growing concern regarding the emergence of visceral leishmaniasis (VL), a disseminated parasitic disease caused by protozoa of the genus Leishmania, as an opportunistic infection in immunocompromised patients. This association has been principally studied in the context of human immunodeficiency virus infection, but VL has also been reported in patients undergoing treatment with immunosuppressive medication for various indications. Here a case of VL in a patient with rheumatoid arthritis undergoing treatment with methotrexate and corticosteroid is presented. Despite the rarity of such incidents, physicians should include VL in the differential diagnosis because this infection, if left untreated, is characterized by significant mortality.

Entities:  

Keywords:  Visceral leishmaniasis; corticosteroids; immunocompromised patients; methotrexate; rheumatoid arthritis

Year:  2017        PMID: 28638689      PMCID: PMC5473451          DOI: 10.5152/eurjrheum.2017.16066

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  10 in total

1.  Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate.

Authors:  Grigorios S Karagiannidis; Marina Mantzourani; John Meletis; Amalia N Anastasopoulou; George A Vaiopoulos
Journal:  J Clin Rheumatol       Date:  2012-01       Impact factor: 3.517

2.  Budd-Chiari syndrome associated with visceral leishmaniasis and factor V Leiden mutation.

Authors:  Emel Gürkan; Cağatay Unsal; Fikri Başlamişli; Didem Arslan
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

Review 3.  Leishmaniasis in immunosuppressed individuals.

Authors:  J van Griensven; E Carrillo; R López-Vélez; L Lynen; J Moreno
Journal:  Clin Microbiol Infect       Date:  2014-02-20       Impact factor: 8.067

Review 4.  Leishmaniasis: clinical syndromes and treatment.

Authors:  B S McGwire; A R Satoskar
Journal:  QJM       Date:  2013-06-05

Review 5.  Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host.

Authors:  Laura Saporito; Giovanni M Giammanco; Simona De Grazia; Claudia Colomba
Journal:  Int J Infect Dis       Date:  2013-02-04       Impact factor: 3.623

6.  Human immunodeficiency virus and leishmaniasis.

Authors:  Navid Ezra; Maria Teresa Ochoa; Noah Craft
Journal:  J Glob Infect Dis       Date:  2010-09

Review 7.  Leishmaniasis among organ transplant recipients.

Authors:  Spinello Antinori; Antonio Cascio; Carlo Parravicini; Roberto Bianchi; Mario Corbellino
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

8.  Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate.

Authors:  Ioannis Venizelos; Zoi Tatsiou; Thomas G Papathomas; Attilio Orazi
Journal:  Int J Infect Dis       Date:  2008-11-20       Impact factor: 3.623

9.  Leishmaniasis worldwide and global estimates of its incidence.

Authors:  Jorge Alvar; Iván D Vélez; Caryn Bern; Mercé Herrero; Philippe Desjeux; Jorge Cano; Jean Jannin; Margriet den Boer
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

Review 10.  Epidemiology of visceral leishmaniasis.

Authors:  Paul D Ready
Journal:  Clin Epidemiol       Date:  2014-05-03       Impact factor: 4.790

  10 in total
  2 in total

1.  Visceral Leishmaniasis in the Mediterranean area.

Authors:  Dèlia Reina; Hèctor Corominas
Journal:  Eur J Rheumatol       Date:  2017-11-02

2.  Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients.

Authors:  Thomas Schwartz; Mogens Jensenius; Bjørn Blomberg; Cathrine Fladeby; Arild Mæland; Frank O Pettersen
Journal:  Trop Dis Travel Med Vaccines       Date:  2019-08-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.